(LFVN) Lifevantage - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US53222K2050
Stock: Supplements, Skincare, Probiotics, Nootropics, Pet Care
Total Rating 22
Risk 39
Buy Signal -0.64
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.65% |
| Yield on Cost 5y | 2.47% |
| Yield CAGR 5y | 24.81% |
| Payout Consistency | 75.5% |
| Payout Ratio | 23.7% |
| Risk 5d forecast | |
|---|---|
| Volatility | 129% |
| Relative Tail Risk | -7.23% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -2.00 |
| Alpha | -94.57 |
| Character TTM | |
|---|---|
| Beta | 1.122 |
| Beta Downside | 1.179 |
| Drawdowns 3y | |
|---|---|
| Max DD | 81.67% |
| CAGR/Max DD | 0.16 |
Description: LFVN Lifevantage January 17, 2026
LifeVantage Corporation (NASDAQ:LFVN) develops and markets nutrigenomic-based dietary supplements, nootropics, weight-management formulas, probiotics, and anti-aging skin-care products, selling primarily through its website and a network of independent consultants from its headquarters in Lehi, Utah.
As of its latest 10-K filing, the company reported FY 2023 revenue of roughly $30 million, a gross margin of ~55 %, and a cash position of $12 million, giving it a market capitalization of about $30 million and a net loss of $8 million, indicating a high cash-burn rate relative to its scale.
The nutraceutical sector is being driven by a projected CAGR of 8-9 % through 2028, fueled by aging demographics, increasing consumer focus on preventive health, and the shift toward e-commerce distribution-trends that directly affect LifeVantage’s growth potential and pricing power.
For a deeper, data-driven valuation, you may want to explore ValueRay’s analytical tools to assess LFVN’s risk-adjusted upside.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 9.18m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -18.19 > 1.0 |
| NWC/Revenue: 8.85% < 20% (prev 7.89%; Δ 0.95% < -1%) |
| CFO/TA 0.06 > 3% & CFO 3.75m > Net Income 9.18m |
| Net Debt (510.0k) to EBITDA (14.0m): 0.04 < 3 |
| Current Ratio: 2.03 > 1.5 & < 3 |
| Outstanding Shares: last quarter (12.7m) vs 12m ago -3.28% < -2% |
| Gross Margin: 79.17% > 18% (prev 0.80%; Δ 7837 % > 0.5%) |
| Asset Turnover: 360.3% > 50% (prev 345.2%; Δ 15.13% > 0%) |
| Interest Coverage Ratio: -28.94 > 6 (EBITDA TTM 14.0m / Interest Expense TTM -375.0k) |
Altman Z'' -6.14
| A: 0.32 (Total Current Assets 38.6m - Total Current Liabilities 19.0m) / Total Assets 61.2m |
| B: -1.69 (Retained Earnings -103.4m / Total Assets 61.2m) |
| C: 0.18 (EBIT TTM 10.9m / Avg Total Assets 61.3m) |
| D: -3.73 (Book Value of Equity -105.1m / Total Liabilities 28.2m) |
| Altman-Z'' Score: -6.14 = D |
Beneish M -2.37
| DSRI: 1.24 (Receivables 4.98m/3.85m, Revenue 220.9m/212.2m) |
| GMI: 1.01 (GM 79.17% / 79.79%) |
| AQI: 1.55 (AQ_t 0.15 / AQ_t-1 0.09) |
| SGI: 1.04 (Revenue 220.9m / 212.2m) |
| TATA: 0.09 (NI 9.18m - CFO 3.75m) / TA 61.2m) |
| Beneish M-Score: -2.37 (Cap -4..+1) = BBB |
What is the price of LFVN shares?
As of February 09, 2026, the stock is trading at USD 5.03 with a total of 496,306 shares traded.
Over the past week, the price has changed by -8.71%, over one month by -20.66%, over three months by -30.26% and over the past year by -75.33%.
Over the past week, the price has changed by -8.71%, over one month by -20.66%, over three months by -30.26% and over the past year by -75.33%.
Is LFVN a buy, sell or hold?
Lifevantage has received a consensus analysts rating of 5.00.
Therefore, it is recommended to buy LFVN.
- StrongBuy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the LFVN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 11 | 118.7% |
| Analysts Target Price | 11 | 118.7% |
| ValueRay Target Price | 4.4 | -12.7% |
LFVN Fundamental Data Overview February 08, 2026
P/E Trailing = 8.3833
P/S = 0.3064
P/B = 1.8034
Revenue TTM = 220.9m USD
EBIT TTM = 10.9m USD
EBITDA TTM = 14.0m USD
Long Term Debt = 10.7m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.89m USD (from shortTermDebt, last quarter)
Debt = 10.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 510.0k USD (from netDebt column, last quarter)
Enterprise Value = 64.9m USD (64.4m + Debt 10.7m - CCE 10.2m)
Interest Coverage Ratio = -28.94 (Ebit TTM 10.9m / Interest Expense TTM -375.0k)
EV/FCF = 38.27x (Enterprise Value 64.9m / FCF TTM 1.70m)
FCF Yield = 2.61% (FCF TTM 1.70m / Enterprise Value 64.9m)
FCF Margin = 0.77% (FCF TTM 1.70m / Revenue TTM 220.9m)
Net Margin = 4.15% (Net Income TTM 9.18m / Revenue TTM 220.9m)
Gross Margin = 79.17% ((Revenue TTM 220.9m - Cost of Revenue TTM 46.0m) / Revenue TTM)
Gross Margin QoQ = 74.00% (prev 80.98%)
Tobins Q-Ratio = 1.06 (Enterprise Value 64.9m / Total Assets 61.2m)
Interest Expense / Debt = 1.00% (Interest Expense 107.0k / Debt 10.7m)
Taxrate = 41.65% (197.0k / 473.0k)
NOPAT = 6.33m (EBIT 10.9m * (1 - 41.65%))
Current Ratio = 2.03 (Total Current Assets 38.6m / Total Current Liabilities 19.0m)
Debt / Equity = 0.32 (Debt 10.7m / totalStockholderEquity, last quarter 33.0m)
Debt / EBITDA = 0.04 (Net Debt 510.0k / EBITDA 14.0m)
Debt / FCF = 0.30 (Net Debt 510.0k / FCF TTM 1.70m)
Total Stockholder Equity = 31.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 14.96% (Net Income 9.18m / Total Assets 61.2m)
RoE = 29.15% (Net Income TTM 9.18m / Total Stockholder Equity 31.5m)
RoCE = 25.74% (EBIT 10.9m / Capital Employed (Equity 31.5m + L.T.Debt 10.7m))
RoIC = 18.79% (NOPAT 6.33m / Invested Capital 33.7m)
WACC = 8.70% (E(64.4m)/V(75.0m) * Re(10.05%) + D(10.7m)/V(75.0m) * Rd(1.00%) * (1-Tc(0.42)))
Discount Rate = 10.05% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.53%
[DCF Debug] Terminal Value 77.49% ; FCFF base≈6.17m ; Y1≈7.01m ; Y5≈9.60m
Fair Price DCF = 11.28 (EV 144.8m - Net Debt 510.0k = Equity 144.3m / Shares 12.8m; r=8.70% [WACC]; 5y FCF grow 16.00% → 2.90% )
EPS Correlation: 67.11 | EPS CAGR: 6.13% | SUE: -0.05 | # QB: 0
Revenue Correlation: 27.61 | Revenue CAGR: -0.58% | SUE: -2.21 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.25 | Chg30d=-0.137 | Revisions Net=+1 | Analysts=3
EPS current Year (2026-06-30): EPS=0.92 | Chg30d=-0.130 | Revisions Net=+1 | Growth EPS=+11.8% | Growth Revenue=-5.6%
EPS next Year (2027-06-30): EPS=0.93 | Chg30d=-0.283 | Revisions Net=+1 | Growth EPS=+1.8% | Growth Revenue=+6.8%
P/S = 0.3064
P/B = 1.8034
Revenue TTM = 220.9m USD
EBIT TTM = 10.9m USD
EBITDA TTM = 14.0m USD
Long Term Debt = 10.7m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.89m USD (from shortTermDebt, last quarter)
Debt = 10.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 510.0k USD (from netDebt column, last quarter)
Enterprise Value = 64.9m USD (64.4m + Debt 10.7m - CCE 10.2m)
Interest Coverage Ratio = -28.94 (Ebit TTM 10.9m / Interest Expense TTM -375.0k)
EV/FCF = 38.27x (Enterprise Value 64.9m / FCF TTM 1.70m)
FCF Yield = 2.61% (FCF TTM 1.70m / Enterprise Value 64.9m)
FCF Margin = 0.77% (FCF TTM 1.70m / Revenue TTM 220.9m)
Net Margin = 4.15% (Net Income TTM 9.18m / Revenue TTM 220.9m)
Gross Margin = 79.17% ((Revenue TTM 220.9m - Cost of Revenue TTM 46.0m) / Revenue TTM)
Gross Margin QoQ = 74.00% (prev 80.98%)
Tobins Q-Ratio = 1.06 (Enterprise Value 64.9m / Total Assets 61.2m)
Interest Expense / Debt = 1.00% (Interest Expense 107.0k / Debt 10.7m)
Taxrate = 41.65% (197.0k / 473.0k)
NOPAT = 6.33m (EBIT 10.9m * (1 - 41.65%))
Current Ratio = 2.03 (Total Current Assets 38.6m / Total Current Liabilities 19.0m)
Debt / Equity = 0.32 (Debt 10.7m / totalStockholderEquity, last quarter 33.0m)
Debt / EBITDA = 0.04 (Net Debt 510.0k / EBITDA 14.0m)
Debt / FCF = 0.30 (Net Debt 510.0k / FCF TTM 1.70m)
Total Stockholder Equity = 31.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 14.96% (Net Income 9.18m / Total Assets 61.2m)
RoE = 29.15% (Net Income TTM 9.18m / Total Stockholder Equity 31.5m)
RoCE = 25.74% (EBIT 10.9m / Capital Employed (Equity 31.5m + L.T.Debt 10.7m))
RoIC = 18.79% (NOPAT 6.33m / Invested Capital 33.7m)
WACC = 8.70% (E(64.4m)/V(75.0m) * Re(10.05%) + D(10.7m)/V(75.0m) * Rd(1.00%) * (1-Tc(0.42)))
Discount Rate = 10.05% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.53%
[DCF Debug] Terminal Value 77.49% ; FCFF base≈6.17m ; Y1≈7.01m ; Y5≈9.60m
Fair Price DCF = 11.28 (EV 144.8m - Net Debt 510.0k = Equity 144.3m / Shares 12.8m; r=8.70% [WACC]; 5y FCF grow 16.00% → 2.90% )
EPS Correlation: 67.11 | EPS CAGR: 6.13% | SUE: -0.05 | # QB: 0
Revenue Correlation: 27.61 | Revenue CAGR: -0.58% | SUE: -2.21 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.25 | Chg30d=-0.137 | Revisions Net=+1 | Analysts=3
EPS current Year (2026-06-30): EPS=0.92 | Chg30d=-0.130 | Revisions Net=+1 | Growth EPS=+11.8% | Growth Revenue=-5.6%
EPS next Year (2027-06-30): EPS=0.93 | Chg30d=-0.283 | Revisions Net=+1 | Growth EPS=+1.8% | Growth Revenue=+6.8%